SOURCE: Skinvisible, Inc.

Skinvisible, Inc.

March 25, 2014 09:05 ET

Skinvisible's Sunscreen Meets New FDA Guidelines for Broad Spectrum and 80 Minute Water-Resistant Claims

Plus Invisicare Patent Supports Eight Hours of Sunscreen Stabilization

LAS VEGAS, NV--(Marketwired - Mar 25, 2014) - Skinvisible Pharmaceuticals, Inc. (OTCBB: SKVI) (OTCQB: SKVI) is pleased to announce that it has successfully completed independent testing to validate its broad spectrum sunscreen claims according to new labeling guidelines by the Food and Drug Administration (FDA) which are designed to help reduce the incidents of skin cancer in the U.S.

Skinvisible has developed sunscreens using its patented Invisicare® delivery technology which includes sunscreens with SPF 15, 30 and 50 (the highest SPF allowed by the FDA). The sunscreens can be labeled with the following claims:

Claim # 1 - Broad-Spectrum: According to the FDA, in order for a sunscreen to be labeled "broad spectrum" it must prove it protects against both UVA and UVB rays by having an SPF (Sun Protection Factor) of at least 15 and a critical wave length of at least 370 nm. Skinvisible's sunscreen has surpassed both of these criteria, allowing Skinvisible's broad spectrum sunscreen label to also state "prevents sunburn, skin cancer and aging due to the sun".

Claim # 2 - Water-Resistant 80 Minutes: The FDA sunscreen water resistant claim requires that a sunscreen must have the same SPF after being in water or sweating for 40 or 80 minutes. Skinvisible's testing was conducted at an independent laboratory specializing in sunscreen testing. The test involved human subjects that applied sunscreen to their arm, followed by the immersion of the arm into a Jacuzzi for 80 minutes (10 minutes in / 10 minutes out). Skinvisible's sunscreen successfully completed this testing and is allowed to use "Water-resistant for 80 Minutes" on its sunscreen label, the longest length of time allowed by the FDA. 

Claim # 3 - Unique Patented Technology / Eight-Hour Photostability: As previously announced, Skinvisible was granted a patent from the United States Patent and Trademark Office entitled "Sunscreen Composition with Enhanced UVA Absorber Stability and Methods", which provides protection until November 2029. Skinvisible successfully formulated a unique Invisicare® delivery system specifically for stabilizing avobenzone; the key sunscreen used in the USA. Data submitted to the US patent office proved that Skinvisible's sunscreen provides a minimum of eight hours of photostability. 

"The global sun care market is projected to reach $9 billion by 2015, therefore Skinvisible is diligently seeking exclusive licensees in the US, Canada and globally for our high quality, exceptional sunscreen formulations," said Terry Howlett, President and CEO. "Skinvisible has put forth a concerted effort to maximize the claims for our sunscreens and therefore we can provide consumers with sun protection which is unsurpassed." He added, "Our broad spectrum sun care product line, made with either Avobenzone or Tinosorb-S, along with our moisturizing "after-sun" products, are fully developed including accelerated stability and initial production. These products are all formulated with patent protection and benefits that will resonate with consumers." 

About Skinvisible Pharmaceuticals, Inc
Skinvisible Pharmaceuticals is a research-and-development company that licenses its proprietary formulations made with Invisicare, its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare holds active ingredients on the skin for extended periods of time resisting both wash off and perspiration along with controlling the release of actives and reducing skin irritation. Skinvisible receives a combination of license fees, and ongoing royalties for its licensed product formulations. Skinvisible's value also lies in its ability to continually generate new IP on topical products formulated with Invisicare.

Forward-Looking Statements: This press release contains 'forward looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10k for the quarter ending October 31, 2013). 

Contact Information